Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden

Abstract

Aims: To evaluate the long-term clinical and economic outcomes associated with insulin detemir and neutral protamine hagedorn (NPH) insulin in combination with mealtime insulin aspart in patients with type 1 diabetes in Sweden, based on data from a two-year, multi-national, open-label, randomized, controlled trial. Methods: Insulin detemir was associated with significant improvements in glycaemic control after 24 months (HbA1c 7.36% versus 7.58%, mean difference -0.22%, p = 0.022) and major hypoglycaemic events (69% risk reduction, p = 0.001) versus NPH. Patients treated with detemir gained less weight (1.7 versus 2.7 kg, P = 0.024). Based on these findings, a published and validated computer model (IMS CORE Diabetes Model) was used to estimate life-expectancy, quality-adjusted life expectancy and both direct medical costs and indirect costs. Results: Basal-bolus therapy with insulin detemir was projected to improve life expectancy by 0.14 years (15.02 ± 0.19 versus 14.88 ± 0.18 years) and quality-adjusted life expectancy by 0.53 quality-adjusted life years (QALYs) versus NPH (8.35 ± 0.11 versus 7.82 ± 0.10 QALYs). Improvements in QALYs were driven by avoided or delayed diabetes-related complications and fewer hypoglycaemic events. Direct medical costs over patient lifetimes were SEK 26,144 higher in the insulin detemir arm (SEK 995,025 ± 19,580 versus 968,881 ± 19,769), leading to an incremental cost-effectiveness ratio of SEK 49,757 per QALY gained. Capturing indirect costs led to insulin detemir being cost saving over patient lifetimes, by SEK 80,113, compared to NPH (SEK 2,959,909 ± 64,727 versus 3,040,022 ± 62,317). Conclusions: Compared with NPH, insulin detemir is likely to be cost-effective from a healthcare payer perspective and dominant from a societal perspective in patients with type 1 diabetes in Sweden.

Keywords

Cost-effectiveness costs insulin detemir NPH insulin Sweden type 1 diabetes

Get full access to this article

View all access options for this article.

References

Karvonen M. , Viik-Kajander M. Incidence of childhood type 1 diabetes worldwide . Diabetes Care 2009;23:1516-26.

Bolin K. , Gip C. , Mork AC , Lindgren B. Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005 - a register-based approach. Diabet Med 2009 ;26(9):928-34.

The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.

Nathan DM , Cleary PA , Backlund JY , Genuth SM , Lachin JM , Orchard TJ , et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353(25):2643-53.

Herman WH , Eastman RC The effects of treatment on the direct costs of diabetes. Diabetes Care 1998;21(Suppl 3): C19-C24.

Triplitt CL , Reasner CA , Isley WL Pharmacotherapy. Chapter 77. Diabetes mellitus. USA: McGraw-Hill ; 2008. pp. 1205-41.

Vague P. , Selam JL , Skeie S. , De LI , Elte JW , Haahr H. , et al. Insulin detemir is associated with more predictable glycaemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26(3):590-6.

Hermansen K. , Fontaine P. , Kukolja KK , Peterkova V. , Leth G. , Gall MA Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia 2004;47(4):622-9.

Russell-Jones D. , Simpson R. , Hylleberg B. , Draeger E. , Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004 ;26(5):724-36.

10.

Bartley PC , Bogoev M. , Larsen J. , Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial . Diabet Med 2008;25(4):442-9.

11.

American Diabetes Association. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27(9):2262-5.

12.

Palmer AJ , Roze S. , Valentine WJ , Minshall ME , Foos V. , Lurati FM , et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Current Med Res Opin 2004 ;20(Suppl 1):5-26.

13.

Palmer AJ , Roze S. , Valentine W. , Minshall M. , Foos V. , Lurati F. , et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Current Med Res Opin 2004;20(Suppl 1):S27-S40.

14.

Farnkvist LM , Lundman BM Outcomes of diabetes care: a population-based study. Int J Qual Health Care 2003;15(4):301-7.

15.

Eeg-Olofsson K. , Cederholm J. , Nilsson PM , Gudbjornsdottir S. , Eliasson B. Glycaemic and risk factor control in type 1 diabetes: results from 13,612 patients in a national diabetes register. Diabetes Care 2007;30(3):496-502.

16.

Clarke P. , Gray A. , Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22(4):340-9.

17.

Tengs TO , Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38(6):583-637.

18.

Australian Institute of Health and Welfare. Diabetes: Australian facts 2002. Report No.: Diabetes Series No. 3; 2002 .

19.

Carrington AL , Mawdsley SK , Morley M. , Kincey J. , Boulton AJ Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract 1996;32(1-2):19-25.

20.

Currie CJ , Morgan CL , Poole CD , Sharplin P. , Lammert M. , McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes . Curr Med Res Opin 2006;22(8):1523-34.

21.

Statistics Sweden. http://www.scbse/templates/print149078asp2008 (accessed 11 January 2006).

22.

The Swedish Association of Local Authorities and Regions (SALAR). Svenska Kommunföorbundet och Landstingsfördundet i Samverkan. The Swedish Association of Local Authorities and Regions (SALAR) 2006. http://sas.lf.se/kppprod/rap_vikt_tot_2004.htm (accessed 11 January 2006).

23.

Henriksson F. Applications of economic models in healthcare: the introduction of pioglitazone in Sweden. Pharmacoeconomics 2002;20(Suppl 1):43-53.

24.

Ghatnekar O. , Persson U. , Willis M. , Odegaard K.

Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four

European countries. Pharmacoeconomics 2001;19(7):767-78.

25.

Dental and Pharmaceutical Benefits Agency (TLV). http://www.tlvse/in-english/2008 (accessed 11 January 2006).

26.

D’Agostino RB , Russell MW , Huse DM , Ellison RC , Silbershatz H. , Wilson PW , et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study . Am Heart J 2000;139(2 Pt 1):272-81.

27.

Stevens RJ , Kothari V. , Adler AI , Stratton IM , Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci [Lond] 2001;101(6):671-9.

28.

Kannel WB , D’Agostino RB , Silbershatz H. , Belanger AJ , Wilson PW , Levy D. Profile for estimating risk of heart failure. Arch Intern Med 1999 ;159(11):1197-204.

29.

Hermansen K. , Madsbad S. , Perrild H. , Kristensen A. , Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001;24(2):296-301.

30.

Home P. , Bartley P. , Russell-Jones D. , Hanaire-Broutin H. , Heeg JE , Abrams P. , et al. Insulin detemir offers improved glycaemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27(5):1081-7.

31.

Palmer AJ , Valentine WJ , Ray JA , Foos V. , Lurati F. , Smith I. , et al. An economic assessment of analogue basalbolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK. Curr Med Res Opin 2007;23(4):895-901.

32.

Palmer AJ , Roze S. , Valentine WJ , Smith I. , Wittrup-Jensen KU Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Curr Med Res Opin 2004;20(11):1729-46.

33.

Valentine WJ , Palmer AJ , Nicklasson L. , Cobden D. , Roze S. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets. Int J Clin Pract 2006;60(9):1138-45.

34.

Palmer AJ , Lammert M. , Hermansen K. [Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark]. Ugeskr Laeger 2008;170(15):1250-4.